Premium
Clinical management of patients receiving cell‐based immunoregulatory therapy
Author(s) -
Hutchinson James A.,
Ahrens Norbert,
Riquelme Paloma,
Walter Lisa,
Gruber Michael,
Böger Carsten A.,
Farkas Stefan,
Scherer Marcus N.,
Broichhausen Christiane,
Bein Thomas,
Schlitt HansJ.,
Fändrich Fred,
Banas Bernhard,
Geissler Edward K.
Publication year - 2014
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.12641
Subject(s) - autoimmunity , immunotherapy , medicine , immunology , cell therapy , transplantation , complementation , transplant rejection , intensive care medicine , cell function , cell , immune system , biology , biochemistry , genetics , gene , phenotype
Administering immunoregulatory cells as medicinal agents is a revolutionary approach to the treatment of immunologically mediated diseases. Isolating, propagating, and modifying cells before applying them to patients allows complementation of specific cellular functions, which opens astonishing new possibilities for gain‐of‐function antigen‐specific treatments in autoimmunity, chronic inflammatory disorders, and transplantation. This critical review presents a systematic assessment of the potential clinical risks posed by cell‐based immunotherapy, focusing on treatment of renal transplant recipients with regulatory macrophages as a concrete example.